Trump's decision to move marijuana to Schedule III could ease taxes and expand medical access, but industry leaders warn it may also trigger stricter federal oversight and new legal risks.

The move to Schedule III marks the greatest change to U.S. drug laws since 1970 and represents a new future for the $32 billion cannabis industry.

Bipartisan House and Senate lawmakers have introduced a bill in Congress to allow doctors to administer Schedule I drugs such as certain psychedelics to patients with life-threatening conditions. The “Freedom to Heal Act”—sponsored by Sens.

July 16 (UPI) --President Donald Trump on Wednesday signed bipartisan legislation that attempts to curb the illegal flow of fentanyl into the United States by reclassifying the opioid as a Schedule 1 drug under the Controlled Substances Act. Trump appeared ...

President Donald Trump is expected to sign an executive order that would fast-track the reclassification of cannabis and acknowledge its medical benefits.

Such a decision would represent one of the ​most significant federal changes to marijuana policy in decades. It could reshape the cannabis industry, ease criminal penalties, unlock billions in research funding and lead to the opening ​of doors long closed ⁠to banks and investors.